You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 4,943,565


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,943,565
Title: Analgesic tablet of aspirin and caffeine containing low-substituted hydroxypropyl cellulose
Abstract:An analogesic tablet containing aspirin, acetaminophen and caffeine of improved dissolution rate containing low-substituted hydroxypropylcellulose.
Inventor(s): Tencza; Thomas M. (Wallington, NJ), Kim; Chung-Bin (Livingston, NJ)
Assignee: Bristol-Myers Squibb Company (New York, NY)
Application Number:07/282,983
Patent Claims: 1. In a tablet containing by weight of the tablet about 22-75% aspirin, about 22-75% acetaminophen and about 4-19% caffeine, said tablet dissolving in a predetermined period of time, the improvement comprising incorporating into said tablet a dissolution enhancing amount of a hydroxypropyl cellulose ether nonionic polymer which has a hydroxypropyl content of from about 10% to about 16% by weight of the polymer, whereby said polymer-containing tablet dissolves in less than said predetermined period of time.

2. The tablet according to claim 1, wherein the hydroxypropyl cellulose is incorporated in the tablet in an amount of from about 0.5% to about 5% by weight, based on the total weight of the tablet.

3. The tablet according to claim 1, wherein the hydroxypropyl cellulose is present in the tablet in an amount of from about 0.8% to about 2.0% by weight, based on the total weight of the tablet.

4. The tablet according to claim 1, wherein the hydroxypropyl content is from about 10% to about 13%.

5. The tablet according to claim 1 wherein the tablet contains, based on the total weight of the tablet, from about 0.5% to about 5% by weight hydroxypropyl cellulose.

6. The tablet according to claim 5, wherein the aspirin is present in an amount of from about 30% to about 45% by weight, the acetaminophen is present in an amount of from about 30% to about 45% by weight, and the caffeine is present in an amount of from about 9% to about 11% by weight.

7. The tablet according to claim 1, wherein the tablet contains from about 150 mg. to about 500 mg. aspirin, from about 150 mg. to about 500 mg. acetaminophen, from about 30 mg. to about 130 mg. caffeine and from about 5 mg. to about 35 mg. of the hydroxypropyl cellulose.

8. The tablet according to claim 1, wherein the tablet contains from about 200 mg. to about 300 mg. aspirin, from about 200 mg. to about 300 mg. acetaminophen, from about 60 mg. to about 70 mg. caffeine and from about 5 mg. to about 10 mg. hydroxypropyl cellulose.

9. In a tablet containing by weight of the tablet about 22-75% aspirin, about 22-75% acetaminophen and about 4-19% caffeine, said tablet dissolving in a predetermined period of time, the improvement comprising incorporating into said tablet, based on the total weight of the tablet, from about 0.5 to about 5% by weight of a cellulose ether nonionic polymer which has a hydroxypropyl content of from about 10% to about 16% by weight of the polymer, whereby said polymer-containing tablet dissolves in less than said predetermined period of time.

10. The tablet according to claim 9, wherein the hydroxypropyl content is from about 10% to about 13%.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.